Fjarde AP Fonden Fourth Swedish National Pension Fund Has $6.51 Million Holdings in Hologic, Inc. $HOLX

Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 91.4% during the 2nd quarter, Holdings Channel.com reports. The fund owned 99,914 shares of the medical equipment provider’s stock after purchasing an additional 47,700 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Hologic were worth $6,510,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. AustralianSuper Pty Ltd bought a new position in shares of Hologic in the second quarter valued at approximately $7,763,000. Nisa Investment Advisors LLC grew its holdings in Hologic by 17.0% during the second quarter. Nisa Investment Advisors LLC now owns 44,770 shares of the medical equipment provider’s stock worth $2,917,000 after buying an additional 6,503 shares in the last quarter. Wealthfront Advisers LLC raised its position in Hologic by 76.7% in the 2nd quarter. Wealthfront Advisers LLC now owns 79,640 shares of the medical equipment provider’s stock valued at $5,189,000 after buying an additional 34,557 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its stake in Hologic by 1.7% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 14,788 shares of the medical equipment provider’s stock valued at $964,000 after acquiring an additional 246 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS purchased a new position in Hologic during the 2nd quarter worth $616,000. 94.73% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on HOLX shares. Evercore ISI set a $78.00 target price on shares of Hologic and gave the company an “outperform” rating in a report on Tuesday, October 7th. Argus upped their price objective on shares of Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. UBS Group lifted their target price on shares of Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, July 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a report on Tuesday, October 21st. Finally, Royal Bank Of Canada raised Hologic from a “sector perform” rating to an “outperform” rating and increased their price target for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have issued a Hold rating to the company. According to MarketBeat.com, Hologic currently has a consensus rating of “Hold” and a consensus price target of $79.23.

Hologic Stock Down 0.0%

Hologic stock opened at $73.98 on Thursday. The firm has a 50 day moving average price of $68.01 and a 200-day moving average price of $64.36. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The company has a market capitalization of $16.45 billion, a P/E ratio of 30.70, a P/E/G ratio of 2.54 and a beta of 0.63.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the business earned $1.06 earnings per share. Hologic’s revenue for the quarter was up 1.2% on a year-over-year basis. As a group, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the transaction, the director owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.